<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">safetyrisk</journal-id><journal-title-group><journal-title xml:lang="ru">Безопасность и риск фармакотерапии</journal-title><trans-title-group xml:lang="en"><trans-title>Safety and Risk of Pharmacotherapy</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2312-7821</issn><issn pub-type="epub">2619-1164</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">safetyrisk-48</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS AND ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Рекомендации по планированию и проведению аудита системы фармаконадзора</article-title><trans-title-group xml:lang="en"><trans-title>Guidelines for the planning and implementation of pharmacovigilance systems audit</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глаголев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Glagolev</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Олефир</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Olefir</surname><given-names>Yu. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Романов</surname><given-names>Б. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Romanov</surname><given-names>B. K.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аляутдин</surname><given-names>Р. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Alyautdin</surname><given-names>R. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральная служба по надзору в сфере здравоохранения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Service for Surveillance in Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научный центр экспертизы средств медицинского применения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2018</year></pub-date><volume>0</volume><issue>3</issue><fpage>5</fpage><lpage>13</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Глаголев С.В., Олефир Ю.В., Романов Б.К., Аляутдин Р.Н., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Глаголев С.В., Олефир Ю.В., Романов Б.К., Аляутдин Р.Н.</copyright-holder><copyright-holder xml:lang="en">Glagolev S.V., Olefir Y.V., Romanov B.K., Alyautdin R.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.risksafety.ru/jour/article/view/48">https://www.risksafety.ru/jour/article/view/48</self-uri><abstract><p>Представлены общие рекомендации по планированию и проведению аудитов системы фармаконадзора держателей регистрационных удостоверений лекарственных препаратов для медицинского применения. Дан обзор общих требований к проведению аудитов и к аудиторской отчетности. Показана роль мастер-файла системы фармаконадзора в планировании аудитов и инспекций. Даны практические рекомендации для уполномоченных по фармаконадзору в компаниях-держателях регистрационных удостоверений по планированию аудитов системы фармаконадзора и отчетности по ним на стратегическом, тактическом и оперативном уровнях.</p></abstract><trans-abstract xml:lang="en"><p>General recommendations for planning and implementing of a risk-based approach to audits of pharmacovigilance systems of Marketing Authorisation Holders are presented. A review of the general requirements for audits and audit reporting is given. The role of the pharmacovigilance system master file in the planning of audits and inspections is discussed. The article contains practical recommendations for the Qualified Person Responsible for Pharmacovigilance in Marketing Authorisation Holders.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>аудит</kwd><kwd>безопасность</kwd><kwd>лекарственное средство</kwd><kwd>лекарственный препарат</kwd><kwd>фармаконадзор</kwd><kwd>audit</kwd><kwd>safety</kwd><kwd>drug</kwd><kwd>pharmacovigilance</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Проект правил надлежащей практики фармаконадзора [Электронный ресурс]: http://www.eurasian- commission.org/ru/act/texnreg/deptexreg/konsultCo- mitet/Pages/drug_products.aspx (дата обращения: 17.03.2016).</mixed-citation><mixed-citation xml:lang="en">Good Pharmacovigilance practice (GVP) [Electronic resource]. — Available from: http://www.eurasiancommission.org/ru/act/texnreg/deptexreg/konsultComitet/Pages/drug_products.aspx (Cited — 17.03.2016).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральный закон «Об обращении лекарственных средств» № 61-ФЗ от 22.12.2014г.</mixed-citation><mixed-citation xml:lang="en">Federal law «On circulation of medicines» ¹ 61-FZ, 22.12.2014 (in Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
